A Study of Pertuzumab Market - Side Effects, Drug Interactions, Warning and precautions | Detailed Study by Coherent Market Insights with Upcoming Trends

Global Pertuzumab Market Analysis

Overview

Pertuzumab is an antineoplastic recombinant monoclonal antibody that binds the human embryonic cell proliferation receptor 2 protein, often known as HER2. The medication inhibits the proliferation of human tumor cells by blocking signaling pathways that lead to growth factors halt and apoptosis (cell death). Genentech, Inc., a division of F. Hoffmann-La Roche AG, developed pertuzumab to help in the therapy of HER2-associated breast cancer. It was authorized by the US Food and Drug Administration for the first time in 2012.

Get Sample PDF Including COVID-19 Impact Analysis: https://www.coherentmarketinsights.com/insight/request-pdf/2256

Drivers

A growing number of clinical trials are being conducted to see if pertuzumab may be used in conjunction with other medications to treat breast cancer. Adjuvant trastuzumab, pertuzumab, and docetaxel in the treatment of early HER2 positive breast cancer are being studied in a phase III clinical trial at Helsinki University Central Hospital. The research began in December 2015 and is expected to be completed by June 2023.

Moreover, the global pertuzumab market is forecast to develop as the number of medical approvals rises. PERJETA, a pertuzumab made by Genentech, Inc., was approved by the US Food and Drug Administration in December 2017 for use in conjunction with trastuzumab and chemotherapy as adjuvant diagnosis of adults with HER2-positive preclinical breast cancer who are at high risk of recurrence.

Furthermore, the global pertuzumab market is likely to benefit from the development of newer anticancer drug delivery systems. In July 2018, Gentech, Inc., in collaboration with Halozyme Therapeutics, Inc., employed Halozyme Therapeutics, Inc.'s patented ENHANZE drug-delivery technology to administer a fixed-dose combination of pertuzumab (PERJETA) and trastuzumab subcutaneously (Herceptin). This research is now through a clinical phase III trial. ENHANZE technology helps to eliminate the necessity for several injections and the amount of time it takes to administer a medicine.

Tailored Information as per niche requirement:

LIMITED TIME OFFER - Hurry Up!

Exclusive offer!!! Purchase the report at a discounted rate!!!

Get Discount For Buyers UPTO 30% OFF On Any Research Report

Buy Now with Discount for Premium Report 2021: https://www.coherentmarketinsights.com/promo/buynow/2256

Restraint                           

The rising cost of anticancer medications is projected to be a key stumbling block to the global pertuzumab market's expansion. The Scottish Medicines Consortium (SMC) blocked access to pertuzumab in England in June 2017, despite the fact that it was available in Europe through the Cancer Drugs Fund (CDF). SMC rejected the medicine because it was not cost effective when pertuzumab was combined with trastuzumab for the treatment of HER2 positive breast cancer.

Furthermore, despite the fact that using pertuzumab with docetaxel and trastuzumab as first-line treatment for HER2 constructive breast cancer has been shown to generate a significant survival benefit, as per a study published in the journal Oncology in September 2015, the treatment is not cost effective in the U.S. The same source added that treating HER2 positive breast cancer with pertuzumab and other medications costs US$ 509,845 against US$ 135,092 if only docetaxel and trastuzumab are used.

Regional Insights

Due to the rising frequency of breast cancer among women in the U.S., North America is projected to dominate the global pertuzumab market. As per the American Cancer Society, 52,710 new instances of invasive breast cancer were detected in women in the U.S. in 2017, with an estimated 40,610 women dying from breast cancer in the same year.

Moreover, due to rising awareness of breast cancer and its care, Asia Pacific is forecast to see considerable growth in the global pertuzumab market. India began the National Cancer Screening Program in November 2016 to raise breast cancer awareness and early detection. This framework attempts to provide a platform for efficient cancer treatment and diagnosis.

Special Requirements?

We value your investment and offer customization as per your requirements.  

Share your precise requirements @ https://www.coherentmarketinsights.com/insight/request-customization/2256

Competitive Landscape

Major companies contributing to the global pertuzumab market are F. Hoffmann-La Roche Limited and Halozyme Therapeutics, Inc.

Table of Content

Global Pertuzumab Market Research Report

Section 1: Global Pertuzumab Industry Overview

Section 2:  Global Economic Impact on Pertuzumab Industry

Section 3:  Global Market Competition by Industry Producers

Section 4:  Global Productions, Revenue (Value), according to Regions

Section 5:  Global Supplies (Production), Consumption, Export, Import, geographically

Section 6:  Global Productions, Revenue (Value), Price Trend, Product Type

Section 7:  Global Market Analysis, on the basis of Application

Section 8:  Pertuzumab Market Pricing Analysis

Section 9:  Market Chain, Sourcing Strategy and Downstream Buyers

Section 10:  Strategies and key policies by Distributors/Suppliers/Traders

Section 11:  Key Marketing Strategy Analysis, by Market Vendors

Section 12:  Market Effect Factors Analysis

Section 13:  Global Pertuzumab Market Forecast

Other Exclusive Reports:

LOGISTICS ROBOTS MARKET ANALYSIS

XEROSTOMIA THERAPEUTICS MARKET ANALYSIS

HUMAN COMBINATION VACCINES MARKET ANALYSIS

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website – www.coherentmarketinsights.com

Contact:

Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837